Skip to content

CDR

Shire set to release Xiidra dry eye drops in U.S.

Shire set to release Xiidra dry eye drops in U.S.

Shire plc has received Food and Drug Administration approval for Xiidra 5% (lifitegrast ophthalmic solution), a twice-daily eye drop solution for dry eye. Plans call for Xiidra to launch in the United States in the third quarter.

Former WBA exec takes reins as Bliss CEO

Former WBA exec takes reins as Bliss CEO

Beauty care veteran Meri Baregamian, a former executive at Walgreens Boots Alliance, has joined spa and beauty products company Bliss as chief executive officer. Bliss said Baregamian took the reins as CEO effective July 7.

Ahold, Delhaize: Merger may close this month

Ahold, Delhaize: Merger may close this month

Delhaize Group and Ahold expect to complete their merger by the end of this month. The companies said Tuesday that the closure of the $29 billion merger deal, announced in June 2015, still awaits final approval by the Federal Trade Commission.

Lannett ships Paxil CR generic

Lannett ships Paxil CR generic

Lannett Co. has been cleared by the Food and Drug Administration to market paroxetine extended-release tablets, an antidepressant, in strengths of 12.5 mg, 25 mg and 37.5 mg. The company said its product, a generic version of Paxil CR extended-release tablets (12.5 mg, 25 mg and 37.

Blistex acquires TUCKS brand

Blistex acquires TUCKS brand

Blistex Inc. has purchased the TUCKS brand of over-the-counter rectal medications from Johnson & Johnson Consumer Inc. Financial terms of the agreement weren’t disclosed. Blistex said Monday that the deal includes the TUCKS businesses in North America as well as international trademark rights.

Chief executive of Sobeys steps down

Chief executive of Sobeys steps down

Marc Poulin has left his posts as president and chief executive officer of Sobeys Inc. and the Canadian food and drug retailer’s parent company, Empire Co. His sudden departure, announced by Empire’s board on Friday, comes just over a week after Empire reported a $2.13 billion net loss for its 2016

WBA’s Gourlay: We’ll work with Valeant

WBA’s Gourlay: We’ll work with Valeant

During the Walgreens Boots Alliance’s conference call this week on its third-quarter results, co-COO Alex Gourlay told analysts that WBA will address Valeant Pharmaceuticals International’s concerns about its distribution arrangement with the company.

Pessina: WBA on target with Rite Aid deal

Pessina: WBA on target with Rite Aid deal

Stefano Pessina said Walgreens Boots Alliance remains in the ballpark in terms of likely store divestitures that the Federal Trade Commission will require for WBA to finalize its deal to acquire Rite Aid Corp. “We still believe that our initial estimate is correct.